James L. L. Tullis Sells 15,000 Shares of Exagen Inc. (NYSE:XGN) Stock

Exagen Inc. (NYSE:XGN) Director James L. L. Tullis sold 15,000 shares of the stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $12.40, for a total value of $186,000.00. Following the completion of the transaction, the director now owns 38,745 shares of the company’s stock, valued at $480,438. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

XGN opened at $12.50 on Wednesday. The business has a 50 day simple moving average of $13.90 and a two-hundred day simple moving average of $14.04. Exagen Inc. has a one year low of $10.29 and a one year high of $29.86.

Exagen (NYSE:XGN) last posted its quarterly earnings results on Tuesday, July 28th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.50. The company had revenue of $8.95 million during the quarter, compared to analysts’ expectations of $4.82 million.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in shares of Exagen by 33.7% during the first quarter. BlackRock Inc. now owns 163,021 shares of the company’s stock valued at $2,598,000 after acquiring an additional 41,057 shares in the last quarter. Wasatch Advisors Inc. raised its position in shares of Exagen by 97.0% during the 1st quarter. Wasatch Advisors Inc. now owns 692,419 shares of the company’s stock worth $11,037,000 after purchasing an additional 341,006 shares during the last quarter. State Street Corp raised its holdings in Exagen by 123.1% in the 1st quarter. State Street Corp now owns 51,469 shares of the company’s stock valued at $820,000 after acquiring an additional 28,404 shares during the last quarter. Cowen AND Company LLC purchased a new stake in shares of Exagen in the 1st quarter valued at approximately $3,820,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Exagen by 674.5% during the 1st quarter. JPMorgan Chase & Co. now owns 8,357 shares of the company’s stock worth $133,000 after purchasing an additional 7,278 shares during the period.

Several research firms recently commented on XGN. Cantor Fitzgerald began coverage on Exagen in a research note on Monday, June 1st. They set an “overweight” rating and a $20.00 target price for the company. Zacks Investment Research cut Exagen from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st.

Exagen Company Profile

Exagen Inc operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia.

Featured Story: What is Liquidity?

Insider Buying and Selling by Quarter for Exagen (NYSE:XGN)

Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.